Company news

Viatris Inc. news in 2023

Viatris Inc.'s news releases, calls and decks from 2023, newest first.

View company

Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders

December 14, 2023

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

December 14, 2023

Viatris to Participate in the Jefferies London Healthcare Conference

November 13, 2023

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

November 12, 2023

Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]

November 6, 2023

Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance

October 29, 2023

Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row

October 22, 2023

Rajiv Malik to Retire as President of Viatris Effective April 1, 2024

October 19, 2023

Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking

October 17, 2023

Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023

October 9, 2023

Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA

September 30, 2023

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.,...

September 26, 2023

Viatris Named to TIME's World's Best Companies 2023 List

September 11, 2023

Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV

September 4, 2023

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

August 6, 2023

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

August 6, 2023

Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva

July 30, 2023

Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023

June 27, 2023

Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023

May 29, 2023

Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors

May 21, 2023

Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year

May 21, 2023

Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

May 16, 2023

Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine

May 15, 2023

Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

May 7, 2023

Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting

April 23, 2023

Viatris to Report First Quarter 2023 Financial Results on May 8, 2023

April 11, 2023

Viatris Wins Summary Judgment in New York Securities Class Action

March 30, 2023

Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

February 26, 2023

Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023

February 26, 2023

Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 14, 2023

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

January 8, 2023

Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division

January 2, 2023

Calls in 2023

Decks in 2023